Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

Abstract: The invention relates to plant-derived cellulose-containing particles useful as strengthening agents in water based systems and to a process for preparing cellulose-containing particles from plant material, which process involves treating said plant material with a peroxide reagent. The process can be controlled to produce cellulose-containing particle having a viscosity up to about 2500 cps.

Abstract: The invention relates to plant-derived cellulose-containing particles useful as rheology modifiers and to a process for preparing cellulose-containing particles from plant material, which process involves treating said plant material with a peroxide reagent. The process can be controlled to produce cellulose-containing particle having a viscosity up to about 7500 or 8000 cps.

Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: A composition and method of preparing a composition is presented wherein the composition comprises cellulose platelets and the cellulose platelets comprise at least 60% cellulose by dry weight, less than 10% pectin by dry weight and at least 5% hemicellulose by dry weight. The composition can be concentrated to at least 25% by weight solids content by pressing under low pressure, whilst retaining the ability to be re suspended within an aqueous medium. The resulting aqueous medium obtains the desired properties of the composition, such as increased viscosity or increased dispersion of pigment particles, for example, to the same extent as the composition before pressing.

Abstract: A biocomposite material (1) and methods of production thereof are described. The biocomposite material (1) exhibits a physical stiffness, strength and toughness comparable to known glass fibre composites while its composition makes it inherently impermeable to water. A general formulation for the biocomposite material (1) is given by the expression: Cel(1-x-y)HPIx HPOy where “Cel” represents cellulose fragments (2), “HPI” represents hydrophilic binders (4), “HPO” represents hydrophobic binders (5) and (x) and (y) quantify the percentage by weight of the hydrophilic (4) and hydrophobic binders (5) present within a material, respectively. The described properties of the biocomposite material (1) are achieved when (x) is within the range of from 0.05 to 0.55 and (y) is within the range of from 0.05 to 0.65.

Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

Abstract: A biocomposite material (1) and methods of production thereof are described. The biocomposite material (1) exhibits a physical stiffness, strength and toughness comparable to known glass fiber composites while its composition makes it inherently impermeable to water. A general formulation for the biocomposite material (1) is given by the expression: Cel(1-x-y) HPIx HPOy where “Cel” represents cellulose fragments (2), “HPI” represents hydrophilic binders (4), “HPO” represents hydrophobic binders (5) and (x) and (y) quantify the percentage by weight of the hydrophilic (4) and hydrophobic binders (5) present within a material, respectively. The described properties of the biocomposite material (1) are achieved when (x) is within the range of from 0.05 to 0.55 and (y) is within the range of from 0.05 to 0.65.

Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

Abstract: Compounds of Formula I that inhibit microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion and their uses in the treatment of diseases linked thereto in animals are described herein.

Abstract: Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO, F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.